Uso de infliximabe na policondrite recidivante

Abstract

Relapsing Polychondritis (RP) is a rare systemic disease of unknown etiology, characterized by recurrent inflammation of cartilaginous structures and other connective tissues, including the ears, nose, joints, respiratory tract, and others. Due to the presence of typical signs and symptoms, biopsy is seldom necessary. Treatment includes corticosteroids, occasionally associated with immunosuppressive agents, but refractory cases are described. Recent reports suggest that anti-TNF agents, such as infliximab, may be of value in patients who do not respond to conventional therapy, but experience with this treatment is scarce. In this paper, the authors report the case of a patient with RP refractory to combined treatment with corticosteroids and immunosuppressive agents, who showed a good response to infliximab.

Relapsing polychondritis: clinical presentations, disease activity and outcomes

“…Emerging treatment options include the use of immunomodulatory agents such as infliximab, etanercept, adalimumab and abatacept [28-31]. Tocilizumab, has shown utility in patients with disease unresponsive to TNF antagonists [32].…”